title: Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study.
abstract: OBJECTIVE
  Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine.
  
  
  METHODS
  Comparative double-blind randomized multicenter study in parallel groups.
  
  
  METHODS
  200 patients of both genders of at least 50 years old with joint pain assessed as ≥30 mm on a visual analogical scale (VAS).
  
  
  METHODS
  Collagen hydrolysate 1200 mg/day or placebo during 6 months.
  
  
  METHODS
  Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-to-treat procedure.
  
  
  RESULTS
  At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p<0.05). However, there was no significant difference between groups at 3 months (44.1% vs. 39.6%, p=0.53). No significant difference in terms of security and tolerability was observed between the two groups.
  
  
  CONCLUSIONS
  This study suggests that collagen hydrolysate 1200 mg/day could increase the number of clinical responders (i.e. improvement of at least 20% on the VAS) compared to placebo. More studies are needed to confirm the clinical interest of this food supplement.
authors.affiliation: Department of Public Health, Epidemiology and Health Economics, University of Liège, Belgium. olivier.bruyere@ulg.ac.be
authors.forename: O
authors.initials: O
authors.lastname: Bruyère
authors.forename: B
authors.initials: B
authors.lastname: Zegels
authors.forename: L
authors.initials: L
authors.lastname: Leonori
authors.forename: V
authors.initials: V
authors.lastname: Rabenda
authors.forename: A
authors.initials: A
authors.lastname: Janssen
authors.forename: C
authors.initials: C
authors.lastname: Bourges
authors.forename: J-Y
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D000368:Aged; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D018771:Arthralgia / Q000188:drug therapy*; D003094:Collagen / Q000494:pharmacology / Q000627:therapeutic use*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D057194:Intention to Treat Analysis; D008297:Male; D008875:Middle Aged; D011492:Protein Hydrolysates / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000700:Analgesics; D011492:Protein Hydrolysates; D003094:Collagen